GlaxoSmithKline News and Research

RSS

Isis Pharmaceuticals reports revenues of $32.3M for fourth-quarter 2009

Isis Pharmaceuticals, Inc. today announced its 2009 financial results and reviewed the highlights of the year. Isis achieved its 2009 financial guidance with pro forma net income of $166.9 million and a pro forma net operating loss (NOL) of $14.2 million compared with its guidance for the year of pro forma net income of more than $145 million and a pro forma NOL in the low to mid $20 million range. Isis also achieved its cash guidance by ending 2009 with $574.3 million of cash, cash equivalents and short-term investments significantly in excess of the $550 million projected.

1 Mar 2010

Biovail reports 33% increase in total revenues for fourth-quarter 2009

Biovail Corporation today announced financial results for the three-month and 12-month periods ending December 31, 2009.

25 Feb 2010

Regulus Therapeutics, GSK announce new collaboration on microRNA therapeutics targeting microRNA-122

Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize microRNA therapeutics targeting microRNA-122 in all fields with Hepatitis C Viral infection (HCV) as the lead indication. Under the terms of the new collaboration, Regulus will receive additional upfront and early-stage milestone payments with the potential to earn more than $150 million in miR-122-related combined payments, and tiered royalties up to double digits on worldwide sales of products.

25 Feb 2010

Adolor announces $14.6M net product sales of ENTEREG for year ended December 31, 2009

Adolor Corporation today reported a net loss of $47.9 million, or $(1.03) per basic and diluted share, for the year ended December 31, 2009, compared to a net loss of $30.1 million, or $(0.65) per basic and diluted share, for the year ended December 31, 2008.

25 Feb 2010

GlaxoSmithKline responds to Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia

Today, GlaxoSmithKline responded to the recently released Senate Committee on Finance's January 2010 "Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia" (the "Staff Report").

25 Feb 2010

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

At the 17th Conference on Retroviruses and Opportunistic Infections (CROI), ViiV Healthcare presented new data across its broad range of investigational and current medicines for the treatment of HIV/AIDS. Highlighted data at the conference included an oral presentation on the investigational integrase inhibitor, S/GSK1349572, as well as data presentations on SELZENTRY® (maraviroc) and EPZICOM® (abacavir/lamivudine).

24 Feb 2010

Senate, FDA reports increasing concerns about controversial diabetes drug

"Hundreds of people taking Avandia, a controversial diabetes medicine, needlessly suffer heart attacks and heart failure each month, according to confidential government reports that recommend the drug be removed from the market ... ," The New York Times reports. "The internal F.D.A. reports are part of a fierce debate within the agency over what to do about Avandia, manufactured by GlaxoSmithKline."

23 Feb 2010

UCSF professor receives 2010 AADR Distinguished Scientist Award

The American Association for Dental Research (AADR) has announced that John Greenspan, University of California, San Francisco (UCSF), is the recipient of the 2010 AADR Distinguished Scientist Award. This award will be presented to Greenspan at the 39th AADR Annual Meeting & Exhibition in Washington, DC, March 3, 2010.

20 Feb 2010

Depomed receives final meeting minutes from FDA for pre-NDA meeting on DM-1796 for PHN

Depomed, Inc. today announced that it has received final meeting minutes from the FDA for a pre-NDA meeting related to DM-1796 for postherpetic neuralgia (PHN) held in December 2009. Depomed also commented on recent public disclosures related to the Complete Response letter from the U.S. Food and Drug Administration regarding the New Drug Application (NDA) for Horizant™ (gabapentin enacarbil) Extended-Release Tablets.

19 Feb 2010

Parker Waichman Alonso applauds GSK for deciding to stop manufacturing denture adhesive products made with zinc

The attorneys of Parker Waichman Alonso LLP applaud GlaxoSmithKline for its decision to voluntarily stop the manufacture, distribution and advertising of all Super PoliGrip denture adhesive products made with zinc.

19 Feb 2010

GSK decides to remove potentially hazardous zinc from denture adhesive products

GlaxoSmithKline, the maker of popular denture adhesives Poligrip and Super Poligrip, announced today that it will remove zinc from all of its denture adhesive products. The pharmaceutical giant has added the potentially hazardous mineral to its adhesives for decades, despite overwhelming evidence that consuming large quantities of zinc over an extended period of time can cause serious neurological damage.

19 Feb 2010

New report shows dramatic rise in medical technology, pharmaceuticals and healthcare costs

Management of Emerging Healthcare Solutions, Inc. (Pinksheets: EHSI) stated that they were encouraged by a new report that parallels the company’s conclusions about the new potential for business in the current healthcare marketplace.

19 Feb 2010

FDA's proposed label changes for LABA asthma medications: GSK reviews

GlaxoSmithKline is reviewing label changes proposed today by the US Food and Drug Administration (FDA) for asthma medications containing long-acting beta-agonists (LABAs), such as GSK's Advair (salmeterol / fluticasone propionate). GSK and makers of the other affected medicines containing LABAs have 30 days to agree with the proposed changes or state why they are not warranted.

19 Feb 2010

Asthma: LABAs should not be used alone

The U.S. Food and Drug Administration today announced that drugs in the class of long-acting beta agonists (LABAs) should never be used alone in the treatment of asthma in children or adults. Manufacturers will be required to include this warning in the product labels of these drugs, along with taking other steps to reduce the overall use of these medications.

19 Feb 2010

Antigenics announces fourth-quarter and full-year 2009 financial results

Antigenics Inc. reported today its results for the quarter and year ended December 31, 2009. The company reported net income attributable to common stockholders of $1.7 million, or $0.02 per share, basic and diluted, for the fourth quarter of 2009, compared with net income attributable to common stockholders in the fourth quarter of 2008 of $3.9 million, or $0.06 per share, basic and diluted.

18 Feb 2010

GSK Consumer Healthcare applauds two smoking cessation organizations for improving smoking cessation aids

GlaxoSmithKline Consumer Healthcare, marketer of nicotine replacement therapy (NRT) products, including Nicorette®, NicoDerm® CQ® and Commit®, applauds two leading smoking cessation organizations for their efforts to improve the regulation of smoking cessation aids designed to help people quit smoking.

18 Feb 2010

FDA issues Complete Response Letter for Horizant in treatment of RLS

GlaxoSmithKline and XenoPort, Inc. Wednesday received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant™ (gabapentin enacarbil) Extended-Release Tablets, an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS).

18 Feb 2010

AAFA launches national PSA on "Two Main Causes of Asthma"

The Asthma and Allergy Foundation of America (AAFA) is launching a national public service announcement (PSA) supported by GlaxoSmithKline titled "Two Main Causes of Asthma." The PSA goal is to communicate an important message to the millions of Americans with asthma: that treating the two main causes of asthma symptoms may help prevent symptoms before they begin. Asthma symptoms include coughing, wheezing, difficulty breathing and chest tightness.

17 Feb 2010

Meda publishes 2009 year-end report

“The Meda Group expects to achieve sales of about SEK 13,000 million and an EBITDA of about SEK 4,200 million for full-year 2009.”

16 Feb 2010

IMPACT Awards acknowledge nonprofit organizations that provide access to healthcare for underserved

The GlaxoSmithKline 14th Annual IMPACT Awards target community-based nonprofits that provide access to healthcare for the underserved. Up to ten organizations in the Pennsylvania counties of Berks, Bucks, Chester, Delaware, Lancaster, Lehigh, Montgomery, and Philadelphia and the City of Camden, New Jersey, will be awarded $40,000 each.

16 Feb 2010

GlaxoSmithKline News and Research

Isis Pharmaceuticals reports revenues of $32.3M for fourth-quarter 2009

Biovail reports 33% increase in total revenues for fourth-quarter 2009

Regulus Therapeutics, GSK announce new collaboration on microRNA therapeutics targeting microRNA-122

Adolor announces $14.6M net product sales of ENTEREG for year ended December 31, 2009

GlaxoSmithKline responds to Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

Senate, FDA reports increasing concerns about controversial diabetes drug

UCSF professor receives 2010 AADR Distinguished Scientist Award

Depomed receives final meeting minutes from FDA for pre-NDA meeting on DM-1796 for PHN

Parker Waichman Alonso applauds GSK for deciding to stop manufacturing denture adhesive products made with zinc

GSK decides to remove potentially hazardous zinc from denture adhesive products

New report shows dramatic rise in medical technology, pharmaceuticals and healthcare costs

FDA's proposed label changes for LABA asthma medications: GSK reviews

Asthma: LABAs should not be used alone

Antigenics announces fourth-quarter and full-year 2009 financial results

GSK Consumer Healthcare applauds two smoking cessation organizations for improving smoking cessation aids

FDA issues Complete Response Letter for Horizant in treatment of RLS

AAFA launches national PSA on "Two Main Causes of Asthma"

Meda publishes 2009 year-end report

IMPACT Awards acknowledge nonprofit organizations that provide access to healthcare for underserved

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News